Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-02-06T01:01:11.778Z Has data issue: false hasContentIssue false
  • English
  • Français

Gonadotropin releasing hormone agonists and hormone replacement theory

Published online by Cambridge University Press:  03 June 2009

R Jeffrey Chang
R Jeffrey Chang*
Affiliation:
Department of Obstetrics and Gynecology, University of California, Davis, School of Medicine, Sacramento, California, USA
*
Department of Obstetrics and Gynecology, University of California, Davis, School of Medicine, Sacramento, California, USA
Get access Rights & Permissions [Opens in a new window]

Extract

It has been clearly demonstrated that GnRHa is a powerful suppressant of ovarian steroidogenesis and, as a result, provides alternative strategies in dealing with certain gynaecological disorders. A concern for the deleterious effects of oestrogen deprivation is underscored by the potential long-term application of these compounds. Available studies indicate that concomitant HRT, whether physiological or pharmacological, may be utilized with good results. However, there is a great need to further explore the benefit and risks of supplementation therapy.

Type
Research Article
Information
Reproductive Medicine Review , Volume 5 , Issue 3 , October 1996 , pp. 139 - 150
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Steingold, KA, Cedars, M, Lu, JKH, Randle, D, Judd, HL, Meldrum, DR. Treatment of endometriosis with a long-acting gonadotropin releasing hormone agonist. Obstet Gynecol 1989; 69: 403–11.Google Scholar
2Henzl, MR, Corson, SL, Moghissi, K, Buttram, VC, Berquist, C, Jacobson, J. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a randomized plaœbo controlled, double-blind study. N Engl J Med 1988; 318: 485–89.CrossRefGoogle Scholar
3Maheux, R, Lemay, A, Merat, P. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil Steril 1987; 47: 227–33.CrossRefGoogle ScholarPubMed
4Muse, K, Cetel, N, Futerman, L, Yen, S. The premenstrual syndrome: effects of medical ovariectomy. N J Engl Med 1987; 311: 1345–49.CrossRefGoogle Scholar
5Chang, RJ, Laufer, LR, Meldrium, DR et al. Steroid secretion in polycystic ovarian disease after suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983: 56: 897–903.CrossRefGoogle ScholarPubMed
6Letterie, GS, Coddington, CC, Winkel, CA et al. Efficacy of a gonadotropin releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 1989; 51: 951–55.CrossRefGoogle ScholarPubMed
7Surrey, ES, Judd, HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992; 75: 558–63.Google ScholarPubMed
8Devogelaer, JP, De Deuxchaisnes, CN, Donnez, J, Thomas, K. LHRH analogues and bone loss. Lancet 1987; 1: 1498.CrossRefGoogle ScholarPubMed
9Johansen, JA, Riis, BJ, Hassager, C, Moen, M, Jacobson, J, Christiansen, C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–706.CrossRefGoogle ScholarPubMed
10Matta, WH, Shaw, RW, Hesp, R, Evans, R. Reversible trabecular bone density bone loss following induced hypoestrogenism with the GnRH analogue burserelin in premenopausal women. Clin Endocrinol 1988; 29: 45–51.CrossRefGoogle Scholar
11Tummon, IS, Ali, A, Pepping, ME, Radwanska, E, Binor, Z, Dmowski, WP. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988; 49: 792–96.CrossRefGoogle ScholarPubMed
12Golan, A, Bukovsky, I, Schneider, D, Ron-El, R, Herman, A, Caspi, E. D-Trip-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. Fertil Steril 1989; 52: 406–11.CrossRefGoogle ScholarPubMed
13Damewood, MD, Schlaff, WD, Hesla, JS, Rock, JA. Interval bone mineral density with long-term gonadotropin-releasing hormone agonist suppression. Fertil Steril 1989; 52: 596–99.CrossRefGoogle ScholarPubMed
14Dawood, MY, Lewis, V, Ramos, J. Cortical trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21–26.CrossRefGoogle ScholarPubMed
15Bianchi, G, Costantini, S, Anserini, P et al. Effects of gonadotropin-releasing hormone agonist on uterine fibroids and bone density. Maturitas 1989; 11: 179–85.CrossRefGoogle ScholarPubMed
16Waibel-Treber, S, Minne, HW, Scharla, SH, Bremen, TH, Ziegler, R, Leyendecker, G. Reversible bone loss in women treated with GnRH agonists for endometriosis and uterine leiomyoma. Hum Reprod 1989; 4: 384–88.CrossRefGoogle ScholarPubMed
17Stevenson, JC, Lees, B, Gardner, R, Shaw, RW. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Horm Res 1989; 32: 161–64.CrossRefGoogle ScholarPubMed
18Rittmaster, RS, Thompson, DL. Effects of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990; 70: 1096–102.CrossRefGoogle ScholarPubMed
19Hencioni, T, Penotti, M, Barbieri-Carones, M, Ortolani, S, Trevisan, C, Polvani, F. Gonadotropin releasing hormone agonist therapy and its effect on bone mass. Gynecol Endocrinol 1991; 5: 49–56.CrossRefGoogle Scholar
20Scialli, AR, Justila, KJ, Simon, JA. Leuprolide acetate and bone mineral density measured by quantitative digitalized radiography. Fertil Steril 1993; 59: 674–76.CrossRefGoogle Scholar
21Sharla, SH, Minne, HW, Waibel-Treber, S et al. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1990; 70: 1055–61.CrossRefGoogle Scholar
22Dodin, S, LeMay, A, Maheux, R, Dumont, M, Turcot-LeMay, L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. J Clin Endocrinol Metab 1990; 70: 1096–102.Google Scholar
23Gudmundson, JA, Ljunghall, S, Berquist, C, Wide, L, Nillius, SJ. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition. J Clin Endocrinol Metab 1987; 65: 159–63.CrossRefGoogle Scholar
24van Leusden, HAIM, Dogterom, AA. Rapid reduction of uterine leiomyomas with monthly injection of D-Trip6-GnRH. Gynecol Endocrinol 1988; 29: 45–51.CrossRefGoogle Scholar
25Ylikorkala, O, Nilsson, CG, Hirvonen, E, Viinikka, L. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis. Gynecol Endocrinol 1990; 4: 251–60.CrossRefGoogle ScholarPubMed
26Riis, BJ, Christiansen, C, Johansen, S, Jacobson, J. Is it possible to prevent bone loss in young women with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70: 920–24.CrossRefGoogle ScholarPubMed
27Samsioe, G, Jannson, J, Mellstom, D, Svanborg, A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas 1985; 7: 335–40.CrossRefGoogle Scholar
28Bhatia, NN, Bergman, A, Karram, MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989; 160: 176–81.CrossRefGoogle ScholarPubMed
29Stampfer, MJ, Colditz, GA, Willett, WC et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756–62.CrossRefGoogle ScholarPubMed
30Bush, TL, Barrett-Connor, E, Cowan, LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–109.CrossRefGoogle ScholarPubMed
31Petitti, DB, Perlman, JA, Sidney, S. Noncontraceptive estrogens and mortality: longterm follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289–93.Google ScholarPubMed
32Hunt, K, Vessey, M, McPherson, K. Mortality in a cohort of long-time users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080–86.CrossRefGoogle Scholar
33Lemay, A, Faure, N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronis treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab 1994; 79: 1716–22.Google Scholar
34Elkind-Hirsch, KE, Anania, C, Mack, M, Malinak, R. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil Steril 1995; 73: 970–78.CrossRefGoogle Scholar
35Can, BR, Breslau, NA, Givens, C, Byrd, W, Barnett-Hamm, C, Marshburn, PA. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995; 80: 1169–78.Google Scholar
36Heiner, JS, Greendale, GA, Kawakami, AK, Lapolt, PS, Fisher, M, Young, D, Judd, HL. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995; 80: 3412–18.Google ScholarPubMed
37Carmina, E, Janni, A, Lobo, RA. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J Clin Endocrinol Metab 1994; 78: 126–30.Google ScholarPubMed
38Titinin, A, Simberg, N, Stenman, U, Ylikorkala, B. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism. J Clin Endocrinol Metab 1994; 79: 447–51.Google Scholar
39Falsetti, L, Pasinetti, E. Treatment of moderate and severe hirsutism by gonadotropin-releasing agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994; 61: 817–22.CrossRefGoogle ScholarPubMed
40Ciotta, L, Cianci, A, Giuffrida, G, Marietta, E, Agliano, A, Palumbo, G. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil Steril 1996; 65: 61–67.CrossRefGoogle ScholarPubMed
41Steingold, K, De Ziegler, D, Cedars, M et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65: 773–78.CrossRefGoogle ScholarPubMed
42Andreyko, J, Monroe, SE, Jaffe, RB. Treatment of hirsutism with a gonadotropin releasing hormone agonist (Nafarelin). J Clin Endocrinol Metab 1986; 63: 854–59.CrossRefGoogle ScholarPubMed
43Burry, KA, Patton, PE, Ilingworth, DR. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. Am J Obstet Gynecol 1989; 160: 1454–61.CrossRefGoogle ScholarPubMed
44Crook, D, Gardner, R, Worthington, M, Nolan, J, Stevenson, JC, Shaw, RW. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors. Horm Res 1989; 32: 157–60.CrossRefGoogle ScholarPubMed
45Berquist, C. Effects of nafarelin versus danazol on lipids and calcium metabolism. Am J Obstet Gynecol 1990; 162: 589–91.CrossRefGoogle Scholar
46Valimaki, M, Nilsson, CG, Roine, R, Ylikorkala, O. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. J Clin Endocrinol Metab 1989; 69: 1097–103.CrossRefGoogle ScholarPubMed
47Surrey, ES, Gambone, JC, Lu, JKH, Judd, HL. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53: 620–26.CrossRefGoogle ScholarPubMed
48Leather, AT, Studd, JWW, Watson, NR, Holland, EFN. The prevention of bone loss in young women treated with GnRH analogues with ‘add-back’ estrogen therapy. Obstet Gynecol 1993; 81: 104–107.Google ScholarPubMed
49Surrey, ES. Steroidal and nonsteroidal ‘add-back’ therapy: extending safety and 100% efficiency of gonadotropin-releasing hormone agonists in the gynecological patient. Fertil Steril 1995; 64: 673–85.Google Scholar
50Surrey, ES, Judd, HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992; 75: 558–63.Google ScholarPubMed
51Cedars, M, Lu, J, Meldrum, D, Jud, H. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990; 75: 641–45.Google ScholarPubMed
52Friedman, AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for two years: a pilot study. Fertil Steril 1989; 51: 526–28.CrossRefGoogle Scholar
53Maheux, R, Lemay, A, Blanchet, P, Fried, J, Pratt, X. Maintained reduction of uterine leiomyoma following addition of hormone replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991; 6: 500–505.CrossRefGoogle ScholarPubMed
54Lemay, A, Dodin, S, Dewailly, S. Long-term use of the low dose LHRH analogue combined with monthly medroxy-progesterone administration. Horm Res 1989; 32: 141–45.CrossRefGoogle ScholarPubMed
55Cirkel, G, Schweppe, KW, Ochs, H, Hanker, JP, Schneider, HPG. LH-RH agonist (burserelin) treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation. Gynecol Obstet 1988; 246: 139–51.Google Scholar
56Meldrum, DR, Chang, RJ, Lu, J, Vale, W, Rivier, J, Judd, HL. ‘Medical oophorectomy’ using a long-acting GnRH agonist - a possible new approach the treatment of endometriosis. J Clin Endocrinol Metab 1982; 54: 1081–84.CrossRefGoogle ScholarPubMed
57Kennedy, SH, Williams, IA, Brodribb, J, Barlow, DH, Shaw, RW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53: 998–1003.CrossRefGoogle ScholarPubMed
58Shaw, RW, Zoladex Endometriosis Study Team. An open randomized comparative study of the effects of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: 265–72.CrossRefGoogle Scholar
59Lemay, A, Maheux, R, Faure, N, Jean, C, Fazekas, ATA. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 1984; 41: 863–69.CrossRefGoogle ScholarPubMed
60Schriock, E, Monroe, SE, Henzl, M, Jaffe, RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 1985; 44: 583–88.CrossRefGoogle ScholarPubMed
61Maouris, P, Dowsett, M, Rose, G, Edmonds, D. A new treatment for endometriosis. Lancet 1989; 11: 1018–20.Google Scholar
62Reid, BA, Gangar, KF, Beard, RW. Severe endometriosis treated with gonadotropin-releasing hormone agonist and continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1992; 99: 344–48.CrossRefGoogle ScholarPubMed
63Friedman, AJ, Barbieri, RB, Doubilet, PM, Fine, C, Schiff, I. A randomized, double-blind trial of a gonadotropin-releasing hormone agonist (leuprolide) with and without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–409.CrossRefGoogle ScholarPubMed
64Carr, B, Marshburn, P, Weatherall, P et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective randomized double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 1993; 76: 1217–23.Google ScholarPubMed
65West, CP, Lumsden, MA, Hillier, H, Sweeting, V, Baird, DT. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 1992; 7: 328–32.CrossRefGoogle ScholarPubMed
66Friedman, AJ, Daly, M, Juneau-Norcross, M et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ‘add-back’ regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993; 76: 1439–45.Google ScholarPubMed
67Hammarback, S, Backstrom, T. Induced anovulation as a treatment of premenstrual tension syndrome - a double blind crossover study with LRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67: 159–63.CrossRefGoogle Scholar
68Mortola, JH, Girton, L, Fisher, U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen-progestin. J Clin Endocrinol Metab 1991; 71: 252A–252F.CrossRefGoogle Scholar
69Muse, K. Gonadotropin-releasing hormone agonist suppressed premenstrual syndrome (PMS): PMS symptom induction by estrogen, progestin or both [Abstract 75:151]. Proceedings of the Annual Meeting of the Society for Gynecological Investigation, 03 1989, San Diego.Google Scholar
70Hammarback, S, Backstrom, T, Holst, J, von Schuoltz, B, Lyrenas, S. Cyclical mood changes as in premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64: 393–97.CrossRefGoogle Scholar